Drug Manufacturers - Specialty & Generic
Compare Stocks
2 / 10Stock Comparison
ASRT vs DBVT
Revenue, margins, valuation, and 5-year total return — side by side.
Biotechnology
ASRT vs DBVT — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | ||
|---|---|---|
| Industry | Drug Manufacturers - Specialty & Generic | Biotechnology |
| Market Cap | $144M | $1712.35T |
| Revenue (TTM) | $119M | $0.00 |
| Net Income (TTM) | $-30M | $-168M |
| Gross Margin | 70.2% | — |
| Operating Margin | -18.1% | — |
| Total Debt | $39M | $22M |
| Cash & Equiv. | $10M | $194M |
ASRT vs DBVT — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| Assertio Holdings, … (ASRT) | 100 | 564.9 | +464.9% |
| DBV Technologies S.… (DBVT) | 100 | 41.2 | -58.8% |
Price return only. Dividends and distributions are not included.
Quick Verdict: ASRT vs DBVT
Each card shows where this stock fits in a portfolio — not just who wins on paper.
ASRT carries the broadest edge in this set and is the clearest fit for income & stability and growth exposure.
- beta 0.72
- Rev growth -5.0%, EPS growth -37.4%, 3Y rev CAGR -8.7%
- -68.7% 10Y total return vs DBVT's -87.0%
DBVT is the clearest fit if your priority is quality.
- 0.3% margin vs ASRT's -24.9%
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | -5.0% revenue growth vs DBVT's -100.0% | |
| Quality / Margins | 0.3% margin vs ASRT's -24.9% | |
| Stability / Safety | Beta 0.72 vs DBVT's 1.26 | |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | +35.3% vs DBVT's +110.4% | |
| Efficiency (ROA) | -10.3% ROA vs DBVT's -89.0% |
ASRT vs DBVT — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
ASRT vs DBVT — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
Income & Cash Flow (Last 12 Months)
DBVT leads this category, winning 1 of 1 comparable metric.
Income & Cash Flow (Last 12 Months)
ASRT and DBVT operate at a comparable scale, with $119M and $0 in trailing revenue.
| Metric | ||
|---|---|---|
| RevenueTrailing 12 months | $119M | $0 |
| EBITDAEarnings before interest/tax | $8M | -$112M |
| Net IncomeAfter-tax profit | -$30M | -$168M |
| Free Cash FlowCash after capex | -$28M | -$151M |
| Gross MarginGross profit ÷ Revenue | +70.2% | — |
| Operating MarginEBIT ÷ Revenue | -18.1% | — |
| Net MarginNet income ÷ Revenue | -24.9% | — |
| FCF MarginFCF ÷ Revenue | -23.7% | — |
| Rev. Growth (YoY)Latest quarter vs prior year | -57.9% | — |
| EPS Growth (YoY)Latest quarter vs prior year | -12.7% | +91.5% |
Valuation Metrics
Evenly matched — ASRT and DBVT each lead in 1 of 2 comparable metrics.
Valuation Metrics
| Metric | ||
|---|---|---|
| Market CapShares × price | $144M | $1712.35T |
| Enterprise ValueMkt cap + debt − cash | $173M | $1712.35T |
| Trailing P/EPrice ÷ TTM EPS | -4.72x | -0.76x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | 20.37x | — |
| Price / SalesMarket cap ÷ Revenue | 1.21x | — |
| Price / BookPrice ÷ Book value/share | 1.52x | 0.66x |
| Price / FCFMarket cap ÷ FCF | — | — |
Profitability & Efficiency
Evenly matched — ASRT and DBVT each lead in 4 of 8 comparable metrics.
Profitability & Efficiency
ASRT delivers a -29.4% return on equity — every $100 of shareholder capital generates $-29 in annual profit, vs $-130 for DBVT. DBVT carries lower financial leverage with a 0.13x debt-to-equity ratio, signaling a more conservative balance sheet compared to ASRT's 0.42x. On the Piotroski fundamental quality scale (0–9), DBVT scores 4/9 vs ASRT's 3/9, reflecting mixed financial health.
| Metric | ||
|---|---|---|
| ROE (TTM)Return on equity | -29.4% | -130.2% |
| ROA (TTM)Return on assets | -10.3% | -89.0% |
| ROICReturn on invested capital | -13.8% | — |
| ROCEReturn on capital employed | -13.9% | -145.7% |
| Piotroski ScoreFundamental quality 0–9 | 3 | 4 |
| Debt / EquityFinancial leverage | 0.42x | 0.13x |
| Net DebtTotal debt minus cash | $29M | -$172M |
| Cash & Equiv.Liquid assets | $10M | $194M |
| Total DebtShort + long-term debt | $39M | $22M |
| Interest CoverageEBIT ÷ Interest expense | -4.45x | -189.82x |
Total Returns (Dividends Reinvested)
ASRT leads this category, winning 6 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in ASRT five years ago would be worth $98,114 today (with dividends reinvested), compared to $3,090 for DBVT. Over the past 12 months, ASRT leads with a +3525.0% total return vs DBVT's +110.4%. The 3-year compound annual growth rate (CAGR) favors ASRT at 52.9% vs DBVT's 6.2% — a key indicator of consistent wealth creation.
| Metric | ||
|---|---|---|
| YTD ReturnYear-to-date | +144.7% | +4.9% |
| 1-Year ReturnPast 12 months | +3525.0% | +110.4% |
| 3-Year ReturnCumulative with dividends | +257.3% | +19.7% |
| 5-Year ReturnCumulative with dividends | +881.1% | -69.1% |
| 10-Year ReturnCumulative with dividends | -68.7% | -87.0% |
| CAGR (3Y)Annualised 3-year return | +52.9% | +6.2% |
Risk & Volatility
ASRT leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
ASRT is the less volatile stock with a 0.72 beta — it tends to amplify market swings less than DBVT's 1.26 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. ASRT currently trades 99.4% from its 52-week high vs DBVT's 76.3% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | ||
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.72x | 1.26x |
| 52-Week HighHighest price in past year | $22.50 | $26.18 |
| 52-Week LowLowest price in past year | $0.58 | $7.53 |
| % of 52W HighCurrent price vs 52-week peak | +99.4% | +76.3% |
| RSI (14)Momentum oscillator 0–100 | 86.4 | 48.1 |
| Avg Volume (50D)Average daily shares traded | 247K | 252K |
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Wall Street rates ASRT as "Hold" and DBVT as "Buy". Consensus price targets imply 131.8% upside for DBVT (target: $46) vs -19.5% for ASRT (target: $18).
| Metric | ||
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Hold | Buy |
| Price TargetConsensus 12-month target | $18.00 | $46.33 |
| # AnalystsCovering analysts | 18 | 15 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | 0 |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
ASRT leads in 2 of 6 categories (Total Returns, Risk & Volatility). DBVT leads in 1 (Income & Cash Flow). 2 tied.
ASRT vs DBVT: Frequently Asked Questions
8 questions · data-driven answers · updated daily
01Is ASRT or DBVT a better buy right now?
Analysts rate DBV Technologies S.
A. (DBVT) a "Buy" — based on 15 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — ASRT or DBVT?
Over the past 5 years, Assertio Holdings, Inc.
(ASRT) delivered a total return of +881. 1%, compared to -69. 1% for DBV Technologies S. A. (DBVT). Over 10 years, the gap is even starker: ASRT returned -68. 7% versus DBVT's -87. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — ASRT or DBVT?
By beta (market sensitivity over 5 years), Assertio Holdings, Inc.
(ASRT) is the lower-risk stock at 0. 72β versus DBV Technologies S. A. 's 1. 26β — meaning DBVT is approximately 74% more volatile than ASRT relative to the S&P 500. On balance sheet safety, DBV Technologies S. A. (DBVT) carries a lower debt/equity ratio of 13% versus 42% for Assertio Holdings, Inc. — giving it more financial flexibility in a downturn.
04Which is growing faster — ASRT or DBVT?
On earnings-per-share growth, the picture is similar: Assertio Holdings, Inc.
grew EPS -37. 4% year-over-year, compared to -347. 5% for DBV Technologies S. A.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — ASRT or DBVT?
DBV Technologies S.
A. (DBVT) is the more profitable company, earning 0. 0% net margin versus -24. 9% for Assertio Holdings, Inc. — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: DBVT leads at 0. 0% versus -18. 1% for ASRT. At the gross margin level — before operating expenses — ASRT leads at 70. 2%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Which pays a better dividend — ASRT or DBVT?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
07Is ASRT or DBVT better for a retirement portfolio?
For long-horizon retirement investors, Assertio Holdings, Inc.
(ASRT) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 72)). Both have compounded well over 10 years (ASRT: -68. 7%, DBVT: -87. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between ASRT and DBVT?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.